Ireland
--:--IST
Recruiting Observational

Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

NCT02586389 · tracked via the Priya Life Science USA tracker
Phase
Observational
Started
2015-10-13
Last updated
2026-10-02

Condition(s) studied

Non-hematologic Cancer

Study summary

This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject is 18 years of age or older; * Subject is willing to provide written informed consent; * Subject has a diagnosis of a non-hematologic cancer, has tumor in the body, and has either; 1. residual tumor tissue available for testing by the Sponsor; or 2. genomic profiling results from an IVD or LDT assay performed on tumor biopsy tissue; or 3. an invasive procedure (biopsy, surgery) scheduled following the Baseline Visit from which residual tumor tissue can be available for testing by the Sponsor. * Subject is able, in the professional opinion of the investigator, to provide whole blood at the Baseline Visit and at the Interim Visits. Exclusion Criteria: * Underwent curative-intent surgery for management of the presently diagnosed tumor, at any time prior to the Baseline Visit. * Underwent targeted or non-targeted chemotherapy, hormone receptor blocking therapy, or radiation therapy prior to the Baseline Visit. * Underwent an invasive procedure (biopsy, surgery, thermal ablation) in the 7 days prior to any blood collection (baseline or follow-up). * Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent.

Primary outcome measure(s)

  • biospecimen sample collection for liquid biopsy assay development — After cancer diagnosis through 5 years of standard of care follow-up visits
    Analysis of circulating tumor DNA (ctDNA) in whole blood will be compared to baseline tumor DNA for concordance of mutations related to cancer.

Trial sites (1)

FacilityCityRegionStatus
Idaho Urology Boise Idaho Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02586389 on ClinicalTrials.gov ↗ ← All trials in the USA